Skip to main content

Table 6 Bayesian method estimates of indirect probabilities of passing different visual acuity thresholds at month 1 for patients with CRVO

From: Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

Improvement or worsening at Month 1

Probability for Group§ (95% CrI)

Relative risk* (95% CrI)

 

Ranibizumab

Dexamethasone

 

Gain ≥20 letters

0.133 (0.082,0.195)

0.063 (0.016,0.153)

0.47 (0.14,1.61)

Gain ≥10 letters and <20 letters

0.326 (0.250,0.407)

0.435 (0.247,0.638)

1.33 (0.79,2.26)

Loss <10 letters and gain <10 letters

0.511 (0.427,0.595)

0.429 (0.264,0.601)

0.84 (0.54,1.30)

Loss ≥10 letters and <20 letters

0.022 (0.005,0.053)

0.038 (0.012,0.085)

1.70 (0.37,7.84)

Loss ≥20 letters

0.007 (0.000,0.027)

0.035 (0.004,0.120)

4.70 (0.32,69.60)

  1. §Mean of 100000 samples from posterior distributions of probability for change in BCVA from baseline category.
  2. *Ratio of mean probabilities with credible interval based on Delta method on log scale.
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us